Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTreatt Regulatory News (TET)

Share Price Information for Treatt (TET)

Share Price is delayed by 15 minutes
Get Live Data
304.00    0.00 (0.00%)
Bid:
304.00
Ask:
304.50
Spread: 0.50 (0.164%)
Market Cap: £179.47m
TET Live PriceLast checked at - London Stock Exchange

Intraday Treatt Share Chart

Form 8.3 - Treatt Plc

18 Sep 2025 13:35

RNS Number : 9305Z
Jefferies International Limited
18 September 2025
Β 

FORM 8.3

Β 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

Β 

1. KEY INFORMATION

Β 

(a) Full name of discloser:

Jefferies International Limited

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

Β 

Β 

Β 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Treatt Plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

Β 

Β 

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

17th September 2025

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

Β 

N/A

Β 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

Β 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in\ 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

Β 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Β 

Β 

Class of relevant security:

Β 

2p ordinary

Β 

Β 

Interests

Short positions

Β 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

609,716

1.027

Β 

Β 

(2) Cash-settled derivatives:

Β 

5,403

0.009

606,380

1.022

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Β 

Β 

Β 

Β 

TOTAL:

615,119

1.037

606,380

1.022

Β 

All interests and all short positions should be disclosed.

Β 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental FormΒ 8 (Open Positions).

Β 

(b) Rights to subscribe for new securities (including directors' and other employee options)

Β 

Class of relevant security in relation to which subscription right exists:

Β 

Details, including nature of the rights concerned and relevant percentages:

Β 

Β 

Β 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Β 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

Β 

The currency of all prices and other monetary amounts should be stated.

Β 

(a) Purchases and sales

Β 

Class of relevant security

Purchase/sale

Β 

Number of securities

Price per unit (GBX)

2p ordinary

Purchase

Β 

Β 

Β 

Β 

Sale

325

Β 518

Β 224

Β 4,575

Β 

5,317

264.4000

265.0000

265.2500

265.5000

Β 

265.4408

Β 

(b) Cash-settled derivative transactions

Β 

Β 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(GBX)

2p ordinary

Β 

Β 

(c) Stock-settled derivative transactions (including options)

Β 

(i) Writing, selling, purchasing or varying

Β 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

Β 

(ii) Exercise

Β 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

Β 

Β 

Β 

Β 

Β 

Β 

(d) Other dealings (including subscribing for new securities)

Β 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

Β 

Β 

Β 

Β 

Β 

Β 

4. OTHER INFORMATION

Β 

(a) Indemnity and other dealing arrangements

Β 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

Β 

(b) Agreements, arrangements or understandings relating to options or derivatives

Β 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

Β 

(c) Attachments

Β 

Is a Supplemental Form 8 (Open Positions) attached?

NO

Β 

Β 

Date of disclosure:

18th September 2025

Contact name:

Robin Greenwood

Telephone number

020 7029 8595

Β 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

Β 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

Β 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

Β 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
RETEAANPFDFSEFA
Date   Source Headline
28th Nov 20177:00 amRNSPlacing to raise £21.6 million
28th Nov 20177:00 amRNSFinal Results
10th Nov 201712:34 pmRNSHolding(s) in Company
2nd Oct 20177:00 amRNSTrading Update
29th Sep 20175:14 pmRNSTotal Voting Rights
26th Sep 20178:54 amRNSHolding(s) in Company
21st Sep 201712:23 pmRNSHolding(s) in Company
21st Aug 201711:09 amRNSDirector/PDMR Shareholding
2nd Aug 20175:07 pmRNSTotal Voting Rights
20th Jul 20171:50 pmRNSDirector/PDMR Shareholding
5th Jun 20171:35 pmRNSBlock Listing Six Monthly Return
23rd May 20179:30 amRNSBlock Listing Application
11th May 20174:05 pmRNSHolding(s) in Company
11th May 20174:01 pmRNSDirector/PDMR Shareholding
10th May 20172:53 pmRNSHolding(s) in Company
9th May 20177:00 amRNSHalf-year Report
5th Apr 20174:41 pmRNSHolding(s) in Company
3rd Apr 20175:25 pmRNSDirector/PDMR Shareholding
31st Mar 20173:57 pmRNSTotal Voting Rights
30th Mar 20177:00 amRNSTrading Statement
27th Mar 20179:30 amRNSHolding(s) in Company
24th Mar 20173:44 pmRNSDirector/PDMR Shareholding
2nd Mar 20174:50 pmRNSHolding(s) in Company
23rd Feb 20177:00 amRNSDirector/PDMR Shareholding
23rd Feb 20177:00 amRNSTrading Statement
20th Feb 20174:03 pmRNSDirector/PDMR Shareholding
14th Feb 20178:15 amRNSHolding(s) in Company
10th Feb 20179:41 amRNSHolding(s) in Company
1st Feb 20172:19 pmRNSDirector/PDMR Shareholding
30th Jan 20175:58 pmRNSNotification of a Transaction of a Director
27th Jan 20174:42 pmRNSResult of AGM
27th Jan 20177:15 amRNSTrading Statement
30th Dec 20167:00 amRNSAnnual Information Update
30th Dec 20167:00 amRNSTotal Voting Rights
22nd Dec 20163:11 pmRNSUpdate on Site Relocation
20th Dec 201610:26 amRNSDirector/PDMR Shareholding
13th Dec 20161:11 pmRNSNotification of Transactions of Directors
9th Dec 20163:05 pmRNSAnnual Financial Report
5th Dec 20164:35 pmRNSBlock listing Interim Review
1st Dec 20162:55 pmRNSVoting Rights and Capital
29th Nov 20167:00 amRNSFinal Results
31st Oct 20164:45 pmRNSDirector/PDMR Shareholding
19th Oct 20162:51 pmRNSDirector/PDMR Shareholding
30th Sep 20167:00 amRNSTrading Update
29th Sep 20161:21 pmRNSTotal Voting Rights
27th Sep 20163:24 pmRNSHolding(s) in Company
22nd Sep 20163:36 pmRNSDirector/PDMR Shareholding
6th Sep 20163:04 pmRNSHolding(s) in Company
5th Sep 201610:41 amRNSHolding(s) in Company
1st Sep 20163:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.